AZ SB1716

Requires health insurers and AHCCCS to reimburse for clozapine (an antipsychotic medication) and prohibits denying, discontinuing, or rationing the drug for patients with valid prescriptions.

Mandates access to alternative blood monitoring methods for clozapine patients, including mobile phlebotomy, point-of-care testing devices, and in-home services for homebound individuals.

Allows patients to waive or modify routine hematological (blood) monitoring requirements through written informed consent after being counseled on risks of agranulocytosis and other side effects.

Extends clozapine access protections to inmates in county jails and state prisons, including during booking, intake, and transfer between facilities.

Prohibits providers from withholding clozapine solely due to missed lab work, inability to access traditional testing locations, or administrative policies, allowing discontinuation only when there is documented imminent and serious medical risk.